<![CDATA[Alixorexton boosts wakefulness in type 1 narcolepsy, shows cognitive and fatigue gains, and hints at ADHD and neurodegenerative uses.]]>

Divergent dFC stability of DMN and SMN in narcolepsy

Narcolepsy type 1 (NT1) is characterized by profound sleep-wake state instability, pointing to a fundamental dysregulation of large-scale brain network dynamics. To elucidate this, we assessed whole-brain dynamic functional connectivity (dFC) stability using resting-state fMRI in 27 patients with NT1 and 25 matched healthy controls. Our analysis revealed a pattern of opposing alterations: patients exhibited significantly increased dFC stability within the bilateral somatomotor network (SMN), concurrent with decreased stability in the medial prefrontal default mode network (Default_PFCm). These opposing alterations were clinically relevant, as increased SMN stability correlated with poorer objective sleep efficiency, and decreased Default_PFCm stability was similarly associated with lower objective sleep efficiency. Here, we identify for the first time this coexisting neural signature of SMN hyper-stability and Default_PFCm instability in NT1. By simultaneously destabilizing higher-order cognitive networks and disinhibiting primary sensorimotor processing, orexin deficiency may contribute to a synergistic dysregulation that blurs sleep-wake boundaries. The divergence in dynamic network stability provides a novel systems-level framework for understanding state instability in NT1.
<![CDATA[ASPIRE survey reveals fatigue and cognitive impairment reduce work abilities and quality of life in narcolepsy and idiopathic hypersomnia, exposing unmet needs.]]>

Imagery Control Therapy and Lucid Dreaming for REM-Related Symptoms in Narcolepsy

Conditions: Narcolepsy Type 1; Hypnagogic Hallucinations; Sleep Paralysis; REM Sleep Intrusion Symptoms; Central Disorders of Hypersomnolence

Interventions: Behavioral: Cognitive Behavioral Therapy for Narcolepsy (CBT-NAR) With Lucid Dreaming and Imagery Control Therapy; Behavioral: Sleep Hygiene Education and Structured Clinical Follow-up

Sponsors: Institute of Behavioral Sleep Medicine, Colombia

Completed
<![CDATA[Experts explain why most narcolepsy patients need combination therapy, not one pill, and how new agents cut daytime sleepiness toward normal.]]>
<![CDATA[Vibrance-1 phase 2 results show alixorexton improves narcolepsy type 1 severity, cognition, and fatigue for 13 weeks with good tolerability.]]>
<![CDATA[Experts explain which narcolepsy meds suit kids—oxybates and pitolisant approvals, stimulant side effects, and key heart-safety checks.]]>
<![CDATA[Learn how DEA scheduling shapes narcolepsy treatment choices, and why emerging orexin agonists may transform daytime sleepiness and cataplexy care.]]>
<![CDATA[Explore today’s narcolepsy care: from sleep hygiene to stimulants, oxybates, and pitolisant—targeting sleepiness and cataplexy.]]>
<![CDATA[Explore today’s narcolepsy care: wake-promoting meds, oxybates for cataplexy, and pitolisant’s histamine boost—plus sleep habits that matter.]]>